The “postantibiotic era” is not coming—it is already here. The ubiquity of lower respiratory tract infections makes community acquired pneumonia (CAP) an evident target in limiting antimicrobial exposure. Results from a new study, published in April 2021 in the Lancet by Dinh and colleagues, boasts success for patients with a 3-day CAP treatment course.
Corey Diamond, PharmD